A phase 1 randomized, participant-blinded, placebo-controlled trial to determine pharmacokinetics (PK) of single high doses of iptacopan
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Iptacopan (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 17 Jan 2024 New trial record
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition